Home » Health Policy » Pharmaceutical Policy and Regulation

Category Archives: Pharmaceutical Policy and Regulation

Follow the Money to Understand How Drug Profits Flow

Only by following the money will a clear understanding emerge of the economic forces roiling the industry and driving price increases. (more…)

Treatment-Specific Payment Approaches: The Case Of Macular Degeneration

Treatment for neovascular or wet age-related macular degeneration (nAMD) is an area where a change in Medicare Part B payment specific to this procedure has far more potential for substantial reductions in spending. (more…)

Pharmaceutical Industry Profits And Research And Development

Paul Ginsburg and Richard Frank question the premise that more innovation is always a good thing.  (more…)

How Health Care Providers Can Help End the Overprescription of Opioids

Battling the opioid epidemic requires flexible, carefully designed, and rapidly evaluated policies.  (more…)

Switch and Save on Medicare Part D

Simply switching prescription drug plans could save seniors and the government billions. (more…)

A Billion Here, a Billion There: Selectively Disclosing Actual Generic Drug Prices Would Save Real Money

Opportunities exist to lower spending on generic drugs—and reduce total health care spending.

(more…)

Reining In Pharmaceutical Costs

The administration and lawmakers should prioritize four actions that could engender more cooperation and improve health over the long-term. (more…)

Follow The Money: The Flow Of Funds In The Pharmaceutical Distribution System

Any government intervention to control drug pricing should be predicated on a clear understanding of the economic forces that drive price increases, and the parties responsible for them. (more…)

Value-based drug pricing makes sense, but is difficult to pull off

Dana Goldman and Anupam Jena discuss the challenges of value-based pricing and health technology assessments. (more…)

Value-Based Pricing For Pharmaceuticals In The Trump Administration

The change in administration is an opportune moment for CMS to assume a leadership role with respect to value-based pricing.  (more…)

Follow CESR on Facebook



Follow Schaeffer on Facebook